facebook twitter linkedin

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.



DISAGREE AGREE

 

October 24, 2011, Krakow, Poland - Selvita, Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS and oncology disorders, as well as provision of non-clinical research services,presented data from two of its oncology programs at the 2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference, November 12-16, 2011, in San Francisco, CA, USA.

Data presented during this conference included new results from the SEL24 program, a group of specific inhibitors of Pim-1 kinase, as well as the first data from SEL120 program, a potentially first in class kinase inhibitor.

A poster presentation entitled "Novel Pim kinase inhibitors for treatment of hematological malignancies and solid tumors" was presented at the poster session A, titled "Therapeutic Agents: Small Molecule Kinase Inhibitors 1" on Sunday, November 13th, 2011 (Abstract #: A243)

A poster presentation entitled "Antitumor activity of SEL120: An orally available small-molecule inhibitor of Haspin kinase, for standalone and combination therapy with AuroraB inhibitors in colorectal cancer" was presented at the poster session B, titled "Therapeutic Agents: Small Molecule Kinase Inhibitors 2" Monday, November 14th, 2011 (Abstract # B242).

"Current and further development of both SEL24 and SEL120 program, presented at the AACR-EORTC-NCI conference, was made possible thanks to the substantial investment received by Selvita through private placement and the debut on the NewConnect market in July 2011 - said Dr Nicolas Beuzen, Selvita's Chief Scientific Officer. SEL24 is currently at the lead optimization stage, with first clinical trials to be initiated in 2012, while SEL120 is currently in the early phase of discovery research. Selvita's strategy assumes sales of both programs, SEL24 in 2012 and SEL120 in the following years, which will allow the company to break-even in 2012."

To download the poster please click here